Raymond James & Associates trimmed its position in Envista Holdings Co. (NYSE:NVST) by 14.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 52,396 shares of the company’s stock after selling 9,072 shares during the quarter. Raymond James & Associates’ holdings in Envista were worth $2,191,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Envista by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 14,897,130 shares of the company’s stock valued at $643,705,000 after purchasing an additional 598,953 shares during the period. Macquarie Group Ltd. raised its holdings in shares of Envista by 771.4% in the 2nd quarter. Macquarie Group Ltd. now owns 4,015,893 shares of the company’s stock valued at $173,527,000 after purchasing an additional 3,555,062 shares during the period. Boston Partners raised its holdings in shares of Envista by 48.8% in the 2nd quarter. Boston Partners now owns 2,945,015 shares of the company’s stock valued at $127,358,000 after purchasing an additional 966,446 shares during the period. Paradice Investment Management LLC raised its holdings in shares of Envista by 4.0% in the 3rd quarter. Paradice Investment Management LLC now owns 2,479,682 shares of the company’s stock valued at $103,676,000 after purchasing an additional 94,304 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Envista by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 2,001,439 shares of the company’s stock valued at $86,482,000 after purchasing an additional 70,471 shares during the period.
Shares of NVST opened at $46.31 on Friday. Envista Holdings Co. has a 12 month low of $33.75 and a 12 month high of $46.88. The firm’s 50 day moving average is $42.71 and its 200-day moving average is $41.96. The stock has a market capitalization of $7.47 billion, a PE ratio of 22.26, a P/E/G ratio of 0.63 and a beta of 1.75. The company has a current ratio of 1.39, a quick ratio of 1.18 and a debt-to-equity ratio of 0.22.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Envista from a “sell” rating to a “hold” rating in a report on Wednesday, January 5th. Morgan Stanley increased their price target on shares of Envista from $42.00 to $45.00 and gave the company an “equal weight” rating in a report on Friday, January 7th. Finally, Bank of America raised shares of Envista from a “neutral” rating to a “buy” rating and lowered their price target for the company from $49.00 to $48.00 in a report on Tuesday, October 26th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $49.40.
In related news, CFO Howard H. Yu sold 657 shares of the stock in a transaction that occurred on Wednesday, November 17th. The shares were sold at an average price of $42.30, for a total transaction of $27,791.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Amir Aghdaei sold 8,434 shares of the stock in a transaction that occurred on Wednesday, December 22nd. The stock was sold at an average price of $44.75, for a total transaction of $377,421.50. The disclosure for this sale can be found here. Insiders have sold 87,487 shares of company stock worth $4,020,190 over the last ninety days. Insiders own 0.82% of the company’s stock.
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Further Reading: Dividend Kings
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.